Loading...
Docoh
Log in Free sign up

Atossa Therapeutics (ATOS)

Employees
Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
AgricultureEnvironmentEscapeForestMaterialsNatureOffsetPackagePandemicRaw MaterialsWasteAccessAffordabilityBenefitsBlackCalifornia Consumer Privacy ActCitizenshipCultureCustomerData PrivacyData SecurityDeathDisabilityDiversityEmployeeEngagementGenderGeneral Data Protection RegulationHealth CareHealthcareHireHiringHuman CapitalInjuryMinorityPay for PerformancePrivacyProduct QualityRecallRecruitRecruitmentReimbursementSafetySkilledSkillsSocietalSocietySupplierSupply ChainTalentTrainingUnionVolunteerWomenAnti-corruptionAssessmentAssuranceAuditBonusBriberyClassifiedCommitmentCorporate GovernanceDepartment ofEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentInnovationInnovativeInvestigationLawsuitLeadershipLitigationLong-termMajorityOverseeOversightPledgingProcurementProxy ContestPurposeQuality StandardR&DReputationReputational RiskResearch and DevelopmentResponsibilityResponsibleSpecial MeetingStrategySustainableTaxVoting Rights
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 13, 2022, the Company held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). The following items of business were considered and voted upon at the Annual Meeting: (1) the election of two Class I directors named in the proxy statement related to the Annual Meeting; (2) the ratification of the selection of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; (3) approval of the amendment to the Atossa Therapeutics, Inc. Certificate of Incorporation to increase the number of authorized shares of common stock by 100,000,000 shares; (4) to conduct an advisory (non-binding) vote on the compensation of our named executive officers as described in the proxy statement related to the Annual Meeting.

The number of shares of Common Stock entitled to vote at the Annual Meeting was 126,624,110. The number of shares of Common Stock present or represented by valid proxy at the annual meeting was 66,236,059. Proposal 1, 2 and 4 passed. Proposal 3 was not ratified. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below:

(i)Election of two Class I Directors

The stockholders elected two Class I directors as set forth below:

NomineeVotes ForVotes
Withheld		Broker
Non-Votes
Steven C. Quay, M.D., Ph.D.28,431,3429,429,71028,375,257
Gregory L. Weaver25,562,28512,298,76728,375,257

(ii)Ratification of Auditors

The stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 as set forth below:

Votes ForVotes AgainstAbstainBroker
Non-Votes
62,676,690920,1612,639,2080

(iii)Ratify the Amendment to the Atossa Therapeutics, Inc. Certificate of Incorporation to increase the number of authorized shares of common stock by 100,000,000 shares

The stockholders did not approve the amendment to the Certificate of Incorporation as follows:

Votes ForVotes AgainstAbstainBroker
Non-Votes
42,926,87623,152,353156,83028,375,257

(iv)Advisory Vote to Approve Executive Compensation

The stockholders approved an advisory non-binding vote on executive compensation as follows:

Votes ForVotes AgainstAbstainBroker
Non-Votes
28,282,3678,268,5961,309,83928,375,257


* * *